Adalimumab

被引：47

作者：

Bain, B ^{[1
]}

Brazil, M ^{[1
]}

机构：

[1] Decis Resources Inc, Waltham, MA 02453 USA

来源：

NATURE REVIEWS DRUG DISCOVERY | 2003年 / 2卷 / 09期

关键词：

D O I：

10.1038/nrd1182

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Adalimumab (Humira; Abbott), an antibody that binds specifically to the inflammatory cytokine TNF-α, was approved by the US FDA for the treatment of moderate to severe rheumatoid arthritis in December 2002. Does the launch of adalimumab, which is the first fully human antibody to be approved as a therapeutic, sound the death knoll for chimeric and humanized antibodies?

引用

页码：693 / 694

页数：2

共 5 条

[1] Development of anti-TNF therapy for rheumatoid arthritis
Feldmann, M
[J]. NATURE REVIEWS IMMUNOLOGY, 2002, 2 (05) : 364 - 371
[2] Anti-TNF-α therapies:: The next generation
Palladino, MA
Bahjat, FR
Theodorakis, EA
Moldawer, LL
[J]. NATURE REVIEWS DRUG DISCOVERY, 2003, 2 (09) : 736 - 746
[3] Therapeutic strategies for rheumatoid arthritis
Smolen, JS
Steiner, G
[J]. NATURE REVIEWS DRUG DISCOVERY, 2003, 2 (06) : 473 - 488
[4] Adalimumab, a fully human anti-tumor necrosis factor a monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate - The ARMADA trial
Weinblatt, ME
Keystone, EC
Furst, DE
Moreland, LW
Weisman, MH
Birbara, CA
Teoh, LA
Fischkoff, SA
Chartash, EK
[J]. ARTHRITIS AND RHEUMATISM, 2003, 48 (01): : 35 - 45
[5] 2002, FDA DRUG APPROVALS L

← 1 →